(19)
(11) EP 3 583 209 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.02.2025 Bulletin 2025/09

(45) Mention of the grant of the patent:
04.12.2024 Bulletin 2024/49

(21) Application number: 18708920.6

(22) Date of filing: 14.02.2018
(51) International Patent Classification (IPC): 
C12N 9/22(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 9/22; C12Y 301/00; C07K 2319/71; C07K 2319/80
(86) International application number:
PCT/EP2018/053717
(87) International publication number:
WO 2018/149888 (23.08.2018 Gazette 2018/34)

(54)

HIGH-FIDELITY CAS9 VARIANTS AND APPLICATIONS THEREOF

HIGH-FIDELITY-CAS9-VARIANTEN UND ANWENDUNGEN DAVON

VARIANTS DE CAS9 HAUTE FIDÉLITÉ ET LEURS APPLICATIONS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 14.02.2017 IT 201700016321

(43) Date of publication of application:
25.12.2019 Bulletin 2019/52

(73) Proprietor: Università Degli Studi Di Trento
38122 Trento (IT)

(72) Inventors:
  • CERESETO, Anna
    38122 Trento (IT)
  • CASINI, Antonio
    38122 Trento (IT)
  • PETRIS, Gianluca
    38122 Trento (IT)
  • INGA, Alberto
    38122 Trento (IT)
  • OLIVIERI, Michele
    38122 Trento (IT)

(74) Representative: Valenza, Silvia et al
Notarbartolo & Gervasi S.p.A. Viale Achille Papa, 30
20149 Milano
20149 Milano (IT)


(56) References cited: : 
WO-A1-2016/164797
US-B1- 9 512 446
 WO-A1-2016/205613
   
  • CASINI A ET AL: "Identification of high-fidelity Cas9 variants using a yeast-based screening", HUMAN GENE THERAPY, vol. 27, no. 11, 18 October 2016 (2016-10-18) - 21 October 2016 (2016-10-21), & CONFERENCE ON CHANGING THE FACE OF MODERN MEDICINE - STEM CELLS AND GENE THERAPY; FLORENCE, ITALY, pages A41
  • IAN M SLAYMAKER ET AL: "Rationally engineered Cas9 nucleases with improved specificity", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 351, no. 6268, 1 January 2016 (2016-01-01), pages 84 - 88, XP002757561, ISSN: 0036-8075, [retrieved on 20151201], DOI: 10.1126/SCIENCE.AAD5227
  • BENJAMIN P. KLEINSTIVER ET AL: "High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects", NATURE, vol. 529, no. 7587, 6 January 2016 (2016-01-06), pages 490 - 495, XP055303390, ISSN: 0028-0836, DOI: 10.1038/nature16526
  • M. JINEK ET AL: "Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation", SCIENCE, vol. 343, no. 6176, 14 March 2014 (2014-03-14), pages 1247997 - 1247997, XP055149157, ISSN: 0036-8075, DOI: 10.1126/science.1247997
 
Remarks:
The complete document including Reference Table(s) and the Sequence Listing(s) can be downloaded from the EPO website
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).